Results 341 to 350 of about 1,467,646 (404)

Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis. [PDF]

Blood Neoplasia
Fonseca R, Liu AJ, Langlais BT, Almader-Douglas D, Vikram HR, Hilal T.   +5 more
europepmc   +1 more source

Effects of Dual Inhibition of VEGF‐A and Angpt‐2 on Angiogenesis and Lymphangiogenesis in an Alkali‐Induced Corneal Injury Model

Genes to Cells, Volume 30, Issue 4, July 2025.
ABSTRACT Corneal neovascularization (CNV) is frequently observed after various corneal injuries and corneal transplantation, leading to impairment of corneal transparency. Lymphangiogenesis and the inflammatory response often accompany CNV. Chemical injury is one of the most common causes of CNV, and alkali injury has been widely used as an animal ...
Hiroshi Kuribayashi, Toshiro Iwagawa, Souta Kadohara, Hirokazu Ohashi, Chihiro Kawaji, Takeru Iida, Tomoya Suzuki, Yuta Inokuchi, Tetsuhiro Soeda, Kosuke Saita, Makoto Aihara, Nobuyuki Ebihara, Takashi Miyai, Sumiko Watanabe   +13 more
wiley   +1 more source

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. [PDF]

Cancers (Basel)
Bangolo A, Amoozgar B, Mansour C, Zhang L, Gill S, Ip A, Cho C.   +6 more
europepmc   +1 more source

Effects of VEGFA and ANGPT2 Antibodies on the Activation of Microglia in the Early Stages of Streptozotocin‐Induced Pathogenesis of Diabetic Retinopathy

Genes to Cells, Volume 30, Issue 4, July 2025.
ABSTRACT Diabetic retinopathy (DR) is known as a microvascular complication, in which various inflammatory symptoms, including activation of microglia, are observed. A model of hyperglycemia resembling type 1 diabetes mellitus (DM) induced in mice by intraperitoneal injection of streptozotocin (STZ) has been widely used. We examined the effects of anti‐
Toshiro Iwagawa, Yuta Inokuchi, Kosuke Saita, Tetsuhiro Soeda, Ayumi Usui‐Ouchi, Makoto Aihara, Sumiko Watanabe   +6 more
wiley   +1 more source

FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia. [PDF]

Cancer Res Commun
Ali A, Phan A, Vaikari V, Park M, Pospiech M, Chu R, Meng Y, MacKay JA, Alachkar H.   +8 more
europepmc   +1 more source

JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

Journal of Cellular and Molecular Medicine, Volume 29, Issue 13, July 2025.
ABSTRACT Advances in biotechnology are set to revolutionise the treatment of haematological malignancies. Current treatments have limited efficacy due to their high toxicity and poor long‐term outcomes, particularly in acute myeloid leukaemia (AML). In 2024–2025, emerging targeted therapies promise improved results with reduced adverse effects.
Akbar M. Shahid, William Vainchenker, Stefan N. Constantinescu   +2 more
wiley   +1 more source

NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control. [PDF]

Cancer Immunol Res
Majocchi S, Lloveras P, Nouveau L, Legrand M, Viandier A, Malinge P, Charreton M, Raymond C, Pace EA, Millard BL, Svensson LA, Kelpšas V, Anceriz N, Salgado-Pires S, Daubeuf B, Magistrelli G, Gueneau F, Moine V, Masternak K, Shang L, Fischer N, Ferlin WG.   +21 more
europepmc   +1 more source

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy. [PDF]

Heliyon
Yang C, Li S, Chen D, Liu D, Yang Y, Guo H, Sun N, Bai X, Li G, Zhang R, Wang T, Zhang L, Peng L, Liu S, Zhang W, Zhao G, Tu X, Tian W.   +17 more
europepmc   +1 more source

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. [PDF]

Front Immunol
Bielski P, Barczyński J, Mikitiuk M, Myrcha M, Rykała K, Boon L, Gąsior W, Hec-Gałązka A, Holak TA, Sitar T.   +9 more
europepmc   +1 more source